solar lentigo.
Conditions
Interventions
Intervention 1: Intervention group: Tranexamic acid at a concentration of 4 mg/ml diluted with lidocaine is injected locally into the lesion every two weeks for up to 5 sessions. Injections are perfor
Sponsors
Arak University of Medical Sciences
Eligibility
Sex/Gender
All
Age
35 Years to No maximum
Inclusion criteria
Inclusion criteria: Age over 35 years Presence of relatively symmetrical solar lentigo lesions on the backs of the hands
Exclusion criteria
Exclusion criteria: pregnancy breastfeeding History of any treatment for solar lentigo within 6 weeks prior to the start of the study Active skin infections in the area where tranexamic acid injections were given Vascular diseases and accidents such as embolism and vascular thrombosis
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of lentigo macules. Timepoint: The number of lentigo macules was assessed before each treatment session and 2 weeks after the last session for both intervention and control groups and recorded in the patient information form. Method of measurement: Counting the number of lentigo macules.;Lentigo Overall Improvement Score. Timepoint: The overall improvement score of solar lentigo was assessed before each treatment session from the second session onwards and 2 weeks after the last session for both intervention and control groups and recorded in the patient information form. Method of measurement: Scoring system.;Subjective assessment of lesion healing. Timepoint: Subjective assessment of lesion improvement is assessed before each treatment session from the second session onwards and 2 weeks after the last session for both intervention and control groups and recorded in the patient information form. Method of measurement: Scoring system.;Assessing complications and pain severity in patients. Timepoint: From the second session onwards, before each session, patients are asked about the side effects of both methods and this is recorded in a questionnaire. Also, from the first session, during the injections, they are asked about the intensity of pain and this is calculated based on the Visual Analogue Scale and recorded in the questionnaire. Method of measurement: question. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAlireza Abbasi
Arak University of Medical Sciences
Outcome results
None listed